新型的糖尿病治疗药物GLP-1受体激动剂,又迎来一个里程碑时刻。 近日,由Aditi R. Saxena领衔的研究团队,在著名期刊《自然·医学》发表全球首个口服小分子GLP-1受体激动剂(danuglipron)的重要临床研究数据[1]。 研究结果表明, danuglipron能显著降低2型糖尿病(T2DM)患者空腹血糖、餐后血糖及HbA1c水平,同时减轻...
在过去的半个世纪里,虽然与肥胖相关疾病如高血压、糖尿病、高脂血症等的治疗取得了巨大进展,但针对肥胖本身的药物(anti-obesity medications, AOMs)治疗却因远期效果不佳或存在安全性的问题举步维艰。不过,对肥胖的发生的病理机制,尤其是对肠-脑交互作用(gut-brain communication)的阐释和理解,正在激发对新的AOM的...
在过去的半个世纪里,虽然与肥胖相关疾病如高血压、糖尿病、高脂血症等的治疗取得了巨大进展,但针对肥胖本身的药物(anti-obesity medications, AOMs)治疗却因远期效果不佳或存在安全性的问题举步维艰。不过,对肥胖的发生的病理机制,尤其...
New study provides answer – ABC News Weight-loss Startups Promising Temporary Use of GLP-1 Medications for Long-term Effects Face Doctor Disagreement GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach The Truth About Compounded GLP-1s That Doctors Need to Know ...
8. Nauck MA. The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism. 2020;103:154031. doi:10.10...
Tufts Experts Weigh in on New Generation of Weight Loss Medications Semaglutide Weight Loss Drugs: Ozempic and Wegovy The Dark Side of GLP-1 Receptor Agonists Study on Weight Loss Maintenance with Exercise and GLP-1 Receptor Agonist Research shows GLP-1 drugs are effective but complex ...
8. Nauck MA. The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism. 2020;103:154031. doi:10.1016/j.metabol.2019.154031 ...
[5] Saxena AR, Frias JP, Brown LS, et al. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(5):e2314493. Published 2023 May 1. do...
GlP-1 receptor agonists are a class of medications that are becoming increasingly popular. Large trials have shown that their use provides reliable weight loss in obese patients and improved glycemic control in diabetic patients. Its use also has broader implications for overall metabolic health and ...
新型的糖尿病治疗药物GLP-1受体激动剂,又迎来一个里程碑时刻。 近日,由Aditi R. Saxena领衔的研究团队,在著名期刊《自然·医学》发表全球首个口服小分子GLP-1受体激动剂(danuglipron)的重要临床研究数据[1]。 研究结果表明, danuglipron能显著降低2型糖尿病(T2DM)患者空腹血糖、餐后血糖及HbA1c水平,同时减轻体重...